ClinicalTrials.gg
RecruitingNCT07667829Updated Oct 30, 2026

Vasopressor Agents in Pulmonary Hypertension Crisis

An interventional study of Norepinephrine and Dopamine in Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Hypertension, Pulmonary, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 30, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Pulmonary Arterial Hypertension with a site in China — 19 open to participants now, 24 under way, 3 of them phase 3. Pulmonary Arterial Hypertension · China.

Planned enrollment
42nd of 56
75 · median 148
Started
2026
with 2 others
No phase
8 of 76
4 open now
Primary completion
2028-12
later than 17 of 23 live
Registered
75th of 76
by date
Lead sponsor
3 of 76
China National Center for Cardiovascular Diseases

Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, this one is the 42nd largest by planned enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 with no phase, reaches primary completion later than 17 of the 23 other live ones, and was the 75th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

19 of the 76 studies in Pulmonary Arterial Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Pulmonary Arterial Hypertension with a site in China, or all of them as a file.
02

Study summary

Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring

03

Conditions studied

  • Pulmonary Arterial Hypertension (PAH)
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  • Hypertension, Pulmonary

Keywords

  • Hypertension, Pulmonary
  • Cardiovascular Diseases
  • Vascular Diseases
  • Dopamine
  • Norepinephrine
  • Epinephrine
  • Haemodynamic Monitoring
  • Efficacy and Safety
  • Chronic thromboembolic pulmonary hypertension
  • Heart Failure
  • Pulmonary circulation
  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 years old;
  2. Signed form;
  3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH);
  4. Presenting with manifestations of pulmonary hypertensive crisis;
  5. Receiving both diagnosis and treatment in-hospital;
  6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.

Exclusion criteria

Exclusion Criteria:

  1. At SCAI stage D or stage E ;
  2. Patients who only receive a diagnosis but no treatment in the hospital;
  3. Uncontrolled hyperthyroidism;
  4. Complicated with angle-closure glaucoma;
  5. to the study drug;
  6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;
  7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);
  8. Pregnancy;
  9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Norepinephrine group

    The initial dose is 0.02 mg/kg/min of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg/kg/min of norepinephrine; the maximum dose of norepinephrine is 0.2 mg/kg/min.

    Drug: Norepinephrine

  • Experimental
    Dopamine group

    The initial dose is 2 μg/kg/min of dopamine; each dose adjustment (increase or decrease) is 2 μg/kg/min of dopamine; the maximum dose of dopamine is 20 μg/kg/min.

    Drug: Dopamine

  • Experimental
    Epinephrine group

    The initial dose is 0.02 μg/kg/min of epinephrine; each adjustment (increase or decrease) is 0.02 μg/kg/min of epinephrine; the maximum dose of epinephrine is 0.2 μg/kg/min

    Drug: Epinephrine

Interventions

  • The initial dose is 0.02 mg/kg/min of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg/kg/min of norepinephrine; the maximum dose of norepinephrine is 0.2 mg/kg/min.

  • The initial dose is 2 μg/kg/min of dopamine; each dose adjustment (increase or decrease) is 2 μg/kg/min of dopamine; the maximum dose of dopamine is 20 μg/kg/min

  • The initial dose is 0.02 μg/kg/min of epinephrine; each adjustment (up or down) is 0.02 μg/kg/min of epinephrine; the maximum dose of epinephrine is 0.2 μg/kg/min

06

What researchers measure

Primary outcomes

  1. All-cause mortality within 28 days

    Time frame: 28 days after enrolment

Secondary outcomes

  1. Haemodynamic parameters

    Time frame: Haemodynamic parameters at H0, H6, H24, H48 and H72

  2. Severe arrhythmia (ventricular tachycardia, ventricular fibrillation)

    Time frame: Time of onset of severe arrhythmia

  3. Adverse effects of vasopressors

    Time frame: Time at which adverse effects occur

  4. Arterial Blood Gas Analysis

    Time frame: H0, H6, H24, H48, H72, Day 7, Day 14, Day 21, Day 28 (if the length of hospital stay is between 7 and 28 days, a test must be performed on the day of discharge)

  5. Vital Signs

    Time frame: Record at H0, H2, H4, H6, H12, H24, H48 and H72 after administration of medication; thereafter, record once every 24 hours until the day of discharge

  6. BNP or NT-proBNP

    Time frame: H0, H24, H48, H72, Day 7, Day 14, Day 21, Day 28 (if the length of hospital stay is between 7 and 28 days, a test must be performed on the day of discharge)

  7. Echocardiographic parameters

    Time frame: H0, H24, H48, H72, Day 7, Day 14, Day 21, Day 28 (if the length of hospital stay is between 7 and 28 days, a measurement must be taken on the day of discharge)

07

Study locations

1 of 3 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 60 non-industry interventional studies with no phase under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 28 months is below that.

Counting every sponsor, half of 65 studies reached it within 42 months; a quarter within 18 and three quarters within 71.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 25, 2026
StartActual
Aug 19, 2026was Jun 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing, Chinano status→Recruiting
  • Guangdong Provincial People's Hospital · Guangzhou, Chinano status→Not yet recruiting
  • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
Oct 30, 2026
Start date
Jun 2026→Aug 19, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing, Chinano status→Recruiting
    • Guangdong Provincial People's Hospital · Guangzhou, Chinano status→Not yet recruiting
    • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
    Start date Jun 2026→Aug 19, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07667829
Responsible party
Qing Gu (Study Chair, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Jun 25, 2026
Start date
Aug 19, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Qing Gu,MD
Contact
guqingfw@126.com
+86 010-88392814

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Norepinephrine · Dopamine · Epinephrine

Start the discussion